Sarepta Begin Period Cash Flow vs Sale Purchase Of Stock Analysis

SRPT Stock  USD 123.71  0.76  0.61%   
Sarepta Therapeutics financial indicator trend analysis is much more than just breaking down Sarepta Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sarepta Therapeutics is a good investment. Please check the relationship between Sarepta Therapeutics Begin Period Cash Flow and its Sale Purchase Of Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Begin Period Cash Flow vs Sale Purchase Of Stock

Begin Period Cash Flow vs Sale Purchase Of Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sarepta Therapeutics Begin Period Cash Flow account and Sale Purchase Of Stock. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Sarepta Therapeutics' Begin Period Cash Flow and Sale Purchase Of Stock is -0.37. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Sale Purchase Of Stock in the same time period over historical financial statements of Sarepta Therapeutics, assuming nothing else is changed. The correlation between historical values of Sarepta Therapeutics' Begin Period Cash Flow and Sale Purchase Of Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Sarepta Therapeutics are associated (or correlated) with its Sale Purchase Of Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Sale Purchase Of Stock has no effect on the direction of Begin Period Cash Flow i.e., Sarepta Therapeutics' Begin Period Cash Flow and Sale Purchase Of Stock go up and down completely randomly.

Correlation Coefficient

-0.37
Relationship DirectionNegative 
Relationship StrengthInsignificant

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Sale Purchase Of Stock

Most indicators from Sarepta Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sarepta Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.At this time, Sarepta Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 30.6 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (23.62) in 2024.
 2023 2024 (projected)
Non Recurring199.2M209.2M
Interest Income67.7M71.0M

Sarepta Therapeutics fundamental ratios Correlations

0.660.960.790.960.34-0.970.90.690.980.810.98-0.30.940.750.980.980.931.00.78-0.30.980.690.630.970.86
0.660.790.30.690.77-0.770.720.120.720.820.57-0.20.670.790.720.710.760.640.57-0.20.690.790.220.760.8
0.960.790.630.970.53-0.990.950.520.990.910.89-0.270.890.80.970.980.990.940.79-0.270.960.790.510.990.95
0.790.30.630.70.11-0.710.630.580.710.510.81-0.380.840.610.80.640.630.80.76-0.380.640.520.40.690.57
0.960.690.970.70.48-0.970.980.540.990.820.89-0.260.90.780.970.960.980.950.85-0.260.940.730.490.990.94
0.340.770.530.110.48-0.50.58-0.420.450.710.2-0.010.370.820.460.390.560.310.56-0.010.340.85-0.310.530.69
-0.97-0.77-0.99-0.71-0.97-0.5-0.95-0.56-0.99-0.88-0.910.33-0.94-0.81-0.99-0.97-0.97-0.96-0.820.33-0.95-0.77-0.51-0.99-0.93
0.90.720.950.630.980.58-0.950.40.960.830.8-0.260.860.810.940.910.970.880.87-0.260.880.770.350.970.96
0.690.120.520.580.54-0.42-0.560.40.590.250.79-0.240.590.070.560.670.470.710.24-0.240.70.00.90.530.29
0.980.720.990.710.990.45-0.990.960.590.850.92-0.260.910.760.980.980.980.960.81-0.260.970.730.550.990.93
0.810.820.910.510.820.71-0.880.830.250.850.73-0.180.760.870.860.830.910.790.74-0.180.810.930.250.890.93
0.980.570.890.810.890.2-0.910.80.790.920.73-0.320.920.660.930.950.850.990.68-0.320.960.60.730.90.75
-0.3-0.2-0.27-0.38-0.26-0.010.33-0.26-0.24-0.26-0.18-0.32-0.53-0.24-0.36-0.24-0.23-0.31-0.351.0-0.23-0.18-0.17-0.27-0.19
0.940.670.890.840.90.37-0.940.860.590.910.760.92-0.530.770.970.880.870.940.81-0.530.870.690.530.920.8
0.750.790.80.610.780.82-0.810.810.070.760.870.66-0.240.770.820.720.80.740.79-0.240.690.970.10.820.85
0.980.720.970.80.970.46-0.990.940.560.980.860.93-0.360.970.820.950.960.970.86-0.360.930.770.490.980.92
0.980.710.980.640.960.39-0.970.910.670.980.830.95-0.240.880.720.950.950.970.71-0.241.00.690.650.970.88
0.930.760.990.630.980.56-0.970.970.470.980.910.85-0.230.870.80.960.950.920.85-0.230.930.80.40.990.98
1.00.640.940.80.950.31-0.960.880.710.960.790.99-0.310.940.740.970.970.920.76-0.310.970.680.650.950.84
0.780.570.790.760.850.56-0.820.870.240.810.740.68-0.350.810.790.860.710.850.76-0.350.680.770.040.820.88
-0.3-0.2-0.27-0.38-0.26-0.010.33-0.26-0.24-0.26-0.18-0.321.0-0.53-0.24-0.36-0.24-0.23-0.31-0.35-0.23-0.18-0.17-0.27-0.19
0.980.690.960.640.940.34-0.950.880.70.970.810.96-0.230.870.690.931.00.930.970.68-0.230.650.690.960.85
0.690.790.790.520.730.85-0.770.770.00.730.930.6-0.180.690.970.770.690.80.680.77-0.180.650.010.790.87
0.630.220.510.40.49-0.31-0.510.350.90.550.250.73-0.170.530.10.490.650.40.650.04-0.170.690.010.50.22
0.970.760.990.690.990.53-0.990.970.530.990.890.9-0.270.920.820.980.970.990.950.82-0.270.960.790.50.94
0.860.80.950.570.940.69-0.930.960.290.930.930.75-0.190.80.850.920.880.980.840.88-0.190.850.870.220.94
Click cells to compare fundamentals

Sarepta Therapeutics Account Relationship Matchups

Sarepta Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.8B3.0B3.1B3.1B3.3B3.4B
Other Current Liab196.7M22.1M15.1M406.5M283.4M297.6M
Total Current Liabilities264.8M416.0M452.7M619.6M653.7M686.3M
Total Stockholder Equity818.2M761.8M928.0M385.0M859.3M902.3M
Property Plant And Equipment Net167.6M282.2M236.7M245.0M357.1M375.0M
Net Debt(105.5M)(429.8M)(977.5M)650.6M968.4M1.0B
Retained Earnings(2.3B)(2.8B)(3.2B)(3.9B)(4.4B)(4.2B)
Accounts Payable68.1M111.1M76.7M95.9M164.9M173.2M
Cash835.1M1.5B2.1B966.8M428.4M298.4M
Non Current Assets Total353.9M499.5M543.9M570.5M685.2M719.5M
Non Currrent Assets Other11.8M13.0M143.3M286.6M292.0M306.6M
Cash And Short Term Investments1.1B1.9B2.1B2.0B1.7B1.8B
Common Stock Total Equity6K7K8K9K8.1K7.7K
Common Stock Shares Outstanding73.6M78.0M81.3M87.6M92.4M97.0M
Short Term Investments803.1M289.7M435.9M1.0B1.2B1.3B
Liabilities And Stockholders Equity1.8B3.0B3.1B3.1B3.3B3.4B
Other Stockholder Equity3.1B3.6B4.1B4.3B5.3B5.6B
Total Liab1.0B2.2B2.2B2.7B2.4B2.5B
Property Plant And Equipment Gross167.6M282.2M349.3M393.9M548.1M575.5M
Total Current Assets1.5B2.5B2.6B2.6B2.6B2.7B
Accumulated Other Comprehensive Income50K3K(20K)(1.7M)918K963.9K
Intangible Assets12.5M13.6M14.2M7.6M29.6M31.1M
Common Stock6K7K8K9K8.1K7.7K
Non Current Liabilities Total739.9M1.8B1.8B2.1B1.8B1.8B
Other Current Assets5.2M4.1M6.1M108.1M140.5M147.5M
Other Assets141.9M295.5M292.9M286.6M1.00.95
Property Plant Equipment129.6M190.4M191.2M245.0M281.7M295.8M
Net Receivables93.9M138.6M171.6M259.7M439.7M461.7M
Short Long Term Debt Total729.6M1.2B1.4B1.6B1.4B1.5B
Other Liab10.2M734.1M628.8M521.9M600.2M630.2M
Long Term Debt681.9M992.5M1.1B1.5B1.1B1.2B
Short Term Debt7.8M193.6M271.7M15.5M141.2M148.2M
Net Tangible Assets805.7M748.1M913.8M377.4M434.0M530.3M
Retained Earnings Total Equity(1.6B)(2.3B)(2.8B)(3.2B)(2.9B)(2.7B)
Long Term Debt Total420.6M681.9M992.5M1.1B1.3B1.3B
Capital Surpluse2.6B3.1B3.6B4.1B4.8B5.0B
Inventory171.4M232.0M186.2M204.0M322.9M339.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.